phenotypeId,phenotypeName,referentConceptId,clinicalDescription,literatureReview,phenotypeNotes
40490918000,Marginal zone lymphoma,40490918,"Overview: (MZL) is a group of indolent (slow growing) NHL B-cell lymphomas, which account for approximately eight percent of all NHL cases. The average age at diagnosis is 60 years, and it is slightly more common in women than in men.Presentation: Assessment: Plan: immunotherapy and chemotherapy. Common initial treatments are bendamustine (Treanda) plus rituximab and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), Prognosis: depends on the type, the stage and location of the disease, the patient’s age and overall health, and any lymphoma-related signs or symptoms.",,
